Nachrichten zur Catalyst Pharmaceuticals Aktie

Catalyst Pharmaceuticals: New Products In Proving Phase

…

Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®

CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…

Catalyst Pharmaceuticals: Revenue Growth Lagging Expense Growth (Rating Downgrade)

…

GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten

^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für die Behandlung von…

GNW-Adhoc: Santheras Partner Catalyst Pharmaceuticals lanciert AGAMREE® (Vamorolon) in den Vereinigten Staaten

^* AGAMREE® ist von der U.S. FDA zugelassen und jetzt in den USA für dieBehandlung von Duchenne-Muskeldystrophie (DMD) bei Patienten…

Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States

Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the…

Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…

Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamrees Launch

…

Catalyst Pharmaceuticals: Until The TEVA ANDA Is Resolved, There Is A Risk

…

Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

CORAL GABLES, Fla., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) today…

Catalyst Pharmaceuticals stock plummets on 10M share Spot Secondary priced at $15

…

Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX)…

Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX)…

GigaCloud Technology Stock, Catalyst Pharma And Knife River Among A Dozen New Stocks On IBD Watchlists

GigaCloud Technology stock, Catalyst Pharmaceuticals, Knife River and Fluence Energy are among the 12 new stocks on IBD watchlists Tuesday.…

Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

CORAL GABLES, Fla., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of Americas Most Successful Small-Cap Companies

Catalyst Ranked #4 on the List Catalyst Ranked #4 on the List…

Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

CORAL GABLES, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company…

Catalyst Pharmaceuticals, Inc. (CPRX) Q3 2023 Earnings Call Transcript

…

Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE®

New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio New Patents Further Reinforce the FIRDAPSE® (amifampridine) Intellectual Patent Portfolio…

Catalyst Pharmaceuticals: Agamree Approval Selloff A Long-Term Buying Opportunity

…

Catalyst Pharmaceuticals Partners with Sofies Journey to Bring Focus on Epilepsy at the 11th Annual Epilepsy Awareness and Education Expo

CORAL GABLES, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage…

GNW-Adhoc: Santhera erhält die U.S. FDA-Zulassung für AGAMREE® (Vamorolon) zur Behandlung von Duchenne-Muskeldystrophie

^Ad-hoc-Mitteilung gemäss Art. 53 KR * Die amerikanische Zulassungsbehörde FDA hat AGAMREE® (Vamorolon) für die …

Catalyst Pharmaceuticals Appoints Richard J. Daly as Chief Executive Officer

Patrick J. McEnany to Retire as CEO and will Continue to Serve as Catalysts Chairman Patrick J. McEnany to Retire…

3 Solid Stocks to Buy for Superb Earnings Acceleration

Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.…

Patrick J. McEnany, Chairman and CEO of Catalyst Pharmaceuticals, Receives Prestigious 2023 Lifetime Achievement Award from BioFlorida

CORAL GABLES, Fla., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or “Company”) (Nasdaq: CPRX), a commercial-stage…

Catalyst Pharmaceuticals to Participate at the 2023 Cantor Global Healthcare Conference

CORAL GABLES, Fla., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical…

Catalyst Pharmaceuticals launches $500M mixed shelf offering - filing

…

5 Analysts Have This to Say About Catalyst Pharmaceuticals

Latest Ratings for CPRX DateFirmActionFromTo Feb 2022HC Wainwright & Co.MaintainsBuy Mar 2021Roth CapitalMaintainsBuy Aug 2020Truist SecuritiesMaintainsBuy …

Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the…

Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update

Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22%…

Form 10-Q CATALYST PHARMACEUTICALS For: Jun 30

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K CATALYST PHARMACEUTICALS For: Jul 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Catalyst Pharma announces retirement of CEO

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Catalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRX

Catalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRX...…

Form 8-K CATALYST PHARMACEUTICALS For: Jul 18

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Catalyst Pharmaceuticals Acquires Exclusive North American License For Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is a Promising Best-In-Class Dissociative Anti-Inflammatory Steroid Treatment for Duchenne Muscular Dystrophy...…

Santhera schliesst Lizenzabkommen für Produktkandidaten Vamorolone ab

Biotechnologie - Das Biotechunternehmen Santhera hat den bereits vor einem Monat angekündigten Lizenzvertrag mit Catalyst Pharmaceuticals nun abgeschlossen....…

Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone

Ad hoc announcement pursuant to Art. 53 LR...…

Santhera schliesst exklusives Lizenzabkommen mit Catalyst Pharmaceuticals für Vamorolone in Nordamerika ab

Ad-hoc-Mitteilung gemäss Art. 53 KR...…

Catalyst Pharmaceutical (CPRX) Dips More Than Broader Markets: What You Should Know

Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $12.66, moving -0.78% from the previous trading session....…

Catalyst Pharmaceutical (CPRX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Catalyst Pharmaceutical (CPRX) closed at $13.53, marking a +1.42% move from the previous day....…

Form 8-K CATALYST PHARMACEUTICALS For: Jun 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Is the Options Market Predicting a Spike in Catalyst Pharmaceuticals (CPRX) Stock?

Investors need to pay close attention to Catalyst Pharmaceuticals (CPRX) stock based on the movements in the options market lately....…

Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is Currently Under Review with the FDA (PDUFA Date of October 26, 2023) for the Treatment of Duchenne Muscular…

Santhera Grants Exclusive North America License for Vamorolone to Catalyst Pharmaceuticals in Deal Valued at up to USD 231 Million Plus Royalties

Ad hoc announcement pursuant to Art. 53 LR...…

Zacks.com featured highlights include Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum

Catalyst Pharmaceuticals, Warby Parker, MakeMyTrip Ltd., Brookfield Renewable Partners & Century Aluminum are part of the Zacks Screen of the…

dpa-AFX ProFeed